InvestorsHub Logo
Followers 188
Posts 28686
Boards Moderated 1
Alias Born 08/29/2012

Re: None

Friday, 08/28/2015 12:47:35 PM

Friday, August 28, 2015 12:47:35 PM

Post# of 2098
ZGNXs competition:
Elite Pharma( ELTP ) had successful results from a pilot bioequivalence study for ELI-201, a TWICE-daily opioid abuse deterrent oxycodone product with abuse deterrent technology. $$$ THREE $$$ different twice daily formulations developed by Elite were tested in the study. The study results demonstrate that all formulations in the study were bioequivalent to the reference drug based on pharmacokinetic measures including peak plasma concentration (Cmax) and area under the curve (AUC) for oxycodone blood plasma levels. The study was a single dose, open label, randomized, four period, four treatment, cross over study in 16 healthy volunteers under fasted conditions.

Next year Elite will have the ONLY Immediate Release Abuse Labeled Oxycodone ELI-200

You Can Tell A Man's Character By The Way He Treats Those Who Can Do Nothing For Him